{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T02:02:53Z","timestamp":1793325773733,"version":"4.5.0"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT1173361"],"award-info":[{"award-number":["GNT1173361"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Australian Research Council Industrial Research Translation Hub","award":["IH190100021"],"award-info":[{"award-number":["IH190100021"]}]},{"name":"Australian Government Department of Higher Education"},{"name":"Royal Australasian College of Physician"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>We assessed trends in moxifloxacin use and efficacy for Mycoplasma genitalium over a decade at Melbourne Sexual Health Centre (MSHC). Specific M. genitalium mutations, namely ParC-S83I, have been associated with moxifloxacin failure. In 2024 MSHC introduced ParC-S83 testing, recommending moxifloxacin for ParC-S83 wild type infections and alternative regimens if the ParC-S83I mutation was detected. We present preliminary impacts of ParC-S83 testing on moxifloxacin use and efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Clients with M. genitalium from 2015 to 2024 were treated with doxycycline preceding macrolide resistance\u2013guided azithromycin or moxifloxacin. Clients with a test of cure 14\u201390 days after completing moxifloxacin who reported &amp;gt; 50% adherence and no condomless sex prior to test of cure were eligible for efficacy analyses. Proportions with 95% CIs were calculated for moxifloxacin use and efficacy, with trends assessed by logistic regression. Moxifloxacin use and efficacy were compared in the 12 months before and after introduction of the ParC-S83 assay.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>From 2015 to 2024, 2611 of 5739 M. genitalium infections received moxifloxacin. Moxifloxacin use increased from 6.7% (n = 19\/282; 95% CI, 4.1%\u201310.3%) in 2015 to 60.3% (n = 482\/800; 95% CI, 56.8%\u201363.7%) in 2023 (Ptrend &amp;lt; .0001). Efficacy analyses included 1623 infections. Moxifloxacin efficacy decreased from 100% (n = 11\/11) in 2015 to 79.3% (n = 238\/300; 95% CI, 74.3%\u201383.8%) in 2023 (Ptrend = .007). After introduction of the ParC-S83 assay, moxifloxacin use decreased from 60.3% (n = 482\/800; 95% CI, 56.8%\u201363.7%) in 2023 to 49.2% (n = 438\/890; 95% CI, 45.9%\u201352.6%) in 2024 (P &amp;lt; .0001) and cure increased from 79.3% (n = 238\/300; 95% CI, 74.3%\u201383.8%) in 2023 to 89.2% (n = 116\/130; 95% CI, 82.6%\u201394.0%; P = .013) in ParC-S83 wild type infections.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Increasing moxifloxacin use and declining efficacy reflects rising resistance in our region. Preliminary data suggest a ParC-S83 assay has the potential to improve moxifloxacin use and cure in this setting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/infdis\/jiag251","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T11:46:57Z","timestamp":1778154417000},"page":"e151-e159","source":"Crossref","is-referenced-by-count":1,"title":["Declining Efficacy of Moxifloxacin for\n                    <i>Mycoplasma genitalium<\/i>\n                    Infection: Time for Fluoroquinolone Resistance\u2013Guided Therapy?"],"prefix":"10.1093","volume":"234","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-3147-0541","authenticated-orcid":false,"given":"Laura G","family":"Matthews","sequence":"first","affiliation":[{"name":"Melbourne Sexual Health Centre, Bayside Health , Melbourne, Victoria ,","place":["Australia"]},{"name":"School of Translational Medicine, Monash University , Melbourne, Victoria ,","place":["Australia"]},{"name":"Melbourne School of Population and Global Health, The University of Melbourne , Parkville, Victoria ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3679-9195","authenticated-orcid":false,"given":"Lenka A","family":"Vodstrcil","sequence":"additional","affiliation":[{"name":"Melbourne Sexual Health Centre, Bayside Health , Melbourne, Victoria ,","place":["Australia"]},{"name":"School of Translational Medicine, Monash University , Melbourne, Victoria ,","place":["Australia"]},{"name":"Melbourne School of Population and Global Health, The University of Melbourne , Parkville, Victoria ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5012-5659","authenticated-orcid":false,"given":"Natasha L","family":"Wild","sequence":"additional","affiliation":[{"name":"Melbourne Sexual Health Centre, Bayside Health , Melbourne, Victoria ,","place":["Australia"]},{"name":"School of Translational Medicine, Monash University , Melbourne, Victoria ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5710-2671","authenticated-orcid":false,"given":"Erica L","family":"Plummer","sequence":"additional","affiliation":[{"name":"Melbourne Sexual Health Centre, Bayside Health , Melbourne, Victoria ,","place":["Australia"]},{"name":"School of Translational Medicine, Monash University , Melbourne, Victoria ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivette","family":"Aguirre","sequence":"additional","affiliation":[{"name":"Melbourne Sexual Health Centre, Bayside Health , Melbourne, Victoria ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1754-4920","authenticated-orcid":false,"given":"Kay","family":"Htaik","sequence":"additional","affiliation":[{"name":"Melbourne Sexual Health Centre, Bayside Health , Melbourne, Victoria ,","place":["Australia"]},{"name":"School of Translational Medicine, Monash University , Melbourne, Victoria ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3330-4433","authenticated-orcid":false,"given":"Gerald L","family":"Murray","sequence":"additional","affiliation":[{"name":"Department of Obstetrics, Gynaecology, and Newborn Health, The University of Melbourne , Parkville, Victoria ,","place":["Australia"]},{"name":"Centre for Women's Infectious Diseases, The Royal Women's Hospital , Parkville, Victoria ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vesna","family":"De Petra","sequence":"additional","affiliation":[{"name":"Melbourne Sexual Health Centre, Bayside Health , Melbourne, Victoria ,","place":["Australia"]},{"name":"Microbiological Diagnostic Unit Public Health Laboratory, The Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Parkville, Victoria ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8782-6128","authenticated-orcid":false,"given":"Michelle","family":"Sait","sequence":"additional","affiliation":[{"name":"Microbiological Diagnostic Unit Public Health Laboratory, The Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Parkville, Victoria ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7789-8360","authenticated-orcid":false,"given":"Norelle","family":"Sherry","sequence":"additional","affiliation":[{"name":"Microbiological Diagnostic Unit Public Health Laboratory, The Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Parkville, Victoria ,","place":["Australia"]},{"name":"Department of Infectious Diseases and Immunology, Austin Health , Heidelberg, Victoria ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catriona S","family":"Bradshaw","sequence":"additional","affiliation":[{"name":"Melbourne Sexual Health Centre, Bayside Health , Melbourne, Victoria ,","place":["Australia"]},{"name":"School of Translational Medicine, Monash University , Melbourne, Victoria ,","place":["Australia"]},{"name":"Melbourne School of Population and Global Health, The University of Melbourne , Parkville, Victoria ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"key":"2026080313231930000_jiag251-B1","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1186\/s12879-015-1041-6","article-title":"Management of Mycoplasma genitalium infections\u2014can we hit a moving target?","volume":"15","author":"Jensen","year":"2015","journal-title":"BMC Infect Dis"},{"key":"2026080313231930000_jiag251-B2","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1128\/CMR.00006-11","article-title":"Mycoplasma genitalium: from chrysalis to multicolored butterfly","volume":"24","author":"Taylor-Robinson","year":"2011","journal-title":"Clin Microbiol Rev"},{"key":"2026080313231930000_jiag251-B3","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/S1473-3099(20)30154-7","article-title":"Prevalence of mutations associated with resistance to macrolides and fluoroquinolones in Mycoplasma genitalium: a systematic review and meta-analysis","volume":"20","author":"Machalek","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"2026080313231930000_jiag251-B4","doi-asserted-by":"crossref","first-page":"101047","DOI":"10.1016\/j.lanmic.2024.101047","article-title":"Evolving patterns of macrolide and fluoroquinolone resistance in Mycoplasma genitalium: an updated systematic review and meta-analysis","volume":"6","author":"Chua","year":"2025","journal-title":"Lancet Microbe"},{"key":"2026080313231930000_jiag251-B5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1071\/SH22134","article-title":"Australian sexually transmitted infection (STI) management guidelines for use in primary care 2022 update","volume":"20","author":"Ong","year":"2023","journal-title":"Sex Health"},{"key":"2026080313231930000_jiag251-B6","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/jdv.17972","article-title":"European guideline on the management of Mycoplasma genitalium infections","volume":"36","author":"Jensen","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026080313231930000_jiag251-B7","volume-title":"Mycoplasma genitalium","author":"Centers for Disease Control and Prevention","year":"2021"},{"key":"2026080313231930000_jiag251-B8","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1177\/0956462416688562","article-title":"Meta-analysis of the efficacy of moxifloxacin in treating Mycoplasma genitalium infection","volume":"28","author":"Li","year":"2017","journal-title":"Int J STD AIDS"},{"key":"2026080313231930000_jiag251-B9","first-page":"147","article-title":"Mycoplasma genitalium infection: current treatment options, therapeutic failure, and resistance-associated mutations","volume":"8","author":"Couldwell","year":"2015","journal-title":"Infect Drug Resist"},{"key":"2026080313231930000_jiag251-B10","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ijantimicag.2010.05.011","article-title":"Emergence of clinical strains of Mycoplasma genitalium harbouring alterations in ParC associated with fluoroquinolone resistance","volume":"36","author":"Shimada","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"2026080313231930000_jiag251-B11","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1128\/JCM.00495-13","article-title":"Fluoroquinolone and macrolide resistance-associated mutations in Mycoplasma genitalium","volume":"51","author":"Tagg","year":"2013","journal-title":"J Clin Microbiol"},{"key":"2026080313231930000_jiag251-B12","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/cid\/ciab1058","article-title":"Combination therapy for Mycoplasma genitalium, and new insights into the utility of parC mutant detection to improve cure","volume":"75","author":"Vodstrcil","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2026080313231930000_jiag251-B13","doi-asserted-by":"crossref","first-page":"S412","DOI":"10.1093\/infdis\/jix132","article-title":"New horizons in Mycoplasma genitalium treatment","volume":"216","author":"Bradshaw","year":"2017","journal-title":"J Infect Dis"},{"key":"2026080313231930000_jiag251-B14","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1093\/cid\/ciad057","article-title":"Gyra mutations in Mycoplasma genitalium and their contribution to moxifloxacin failure: time for the next generation of resistance-guided therapy","volume":"76","author":"Murray","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026080313231930000_jiag251-B15","doi-asserted-by":"crossref","first-page":"105911","DOI":"10.1016\/j.ijantimicag.2020.105911","article-title":"Molecular basis of antimicrobial resistance in Mycoplasma genitalium","volume":"55","author":"van der Schalk","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"2026080313231930000_jiag251-B16","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1099\/00222615-47-12-1115","article-title":"Comparative susceptibilities of various AIDS-associated and human urogenital tract mycoplasmas and strains of Mycoplasma pneumoniae to 10 classes of antimicrobial agent in vitro","volume":"47","author":"Hannan","year":"1998","journal-title":"J Med Microbiol"},{"key":"2026080313231930000_jiag251-B17","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1128\/JCM.02328-10","article-title":"Comparison of two Mycoplasma genitalium real-time PCR detection methodologies","volume":"49","author":"Twin","year":"2011","journal-title":"J Clin Microbiol"},{"key":"2026080313231930000_jiag251-B18","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1093\/jac\/dkaa542","article-title":"Mycoplasma genitalium infections can comprise a mixture of both fluoroquinolone-susceptible and fluoroquinolone-resistant strains","volume":"76","author":"Sweeney","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2026080313231930000_jiag251-B19","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1128\/jcm.29.2.297-301.1991","article-title":"Reliability of diagnosing bacterial vaginosis is improved by a standardized method of Gram stain interpretation","volume":"29","author":"Nugent","year":"1991","journal-title":"J Clin Microbiol"},{"key":"2026080313231930000_jiag251-B20","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1093\/jac\/dkaf142","article-title":"Efficacy and tolerability of the combination of minocycline and metronidazole for macrolide-resistant Mycoplasma genitalium","volume":"80","author":"Htaik","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"2026080313231930000_jiag251-B21","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1093\/cid\/ciy477","article-title":"Outcomes of resistance-guided sequential treatment of Mycoplasma genitalium infections: a prospective evaluation","volume":"68","author":"Read","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2026080313231930000_jiag251-B22","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1093\/cid\/ciz1031","article-title":"Resistance-guided antimicrobial therapy using doxycycline-moxifloxacin and doxycycline-2.5 g azithromycin for the treatment of Mycoplasma genitalium infection: efficacy and tolerability","volume":"71","author":"Durukan","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2026080313231930000_jiag251-B23","doi-asserted-by":"crossref","first-page":"ofaa536","DOI":"10.1093\/ofid\/ofaa536","article-title":"Sexually transmitted infection diagnoses and access to a sexual health service before and after the national lockdown for COVID-19 in Melbourne, Australia","volume":"8","author":"Chow","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2026080313231930000_jiag251-B24","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1136\/sextrans-2017-053384","article-title":"Prevalence of Mycoplasma genitalium in different population groups: systematic review and meta-analysis","volume":"94","author":"Baumann","year":"2018","journal-title":"Sex Transm Infect"},{"key":"2026080313231930000_jiag251-B25","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1136\/sextrans-2017-053480","article-title":"Mycoplasma genitalium: high prevalence of resistance to macrolides and frequent anorectal infection in men who have sex with men in western Sydney","volume":"94","author":"Couldwell","year":"2018","journal-title":"Sex Transm Infect"},{"key":"2026080313231930000_jiag251-B26","doi-asserted-by":"crossref","first-page":"719","DOI":"10.3201\/eid2504.181258","article-title":"Symptoms, sites, and significance of Mycoplasma genitalium in men who have sex with men","volume":"25","author":"Read","year":"2019","journal-title":"Emerg Infect Dis"},{"key":"2026080313231930000_jiag251-B27","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/OLQ.0000000000001009","article-title":"Men who have sex with men with Mycoplasma genitalium-positive nongonococcal urethritis are more likely to have macrolide-resistant strains than men with only female partners: a prospective study","volume":"46","author":"McIver","year":"2019","journal-title":"Sex Transm Dis"},{"key":"2026080313231930000_jiag251-B28","doi-asserted-by":"crossref","first-page":"e558","DOI":"10.1016\/S1473-3099(23)00356-0","article-title":"Frequent screening for asymptomatic chlamydia and gonorrhoea infections in men who have sex with men: time to re-evaluate?","volume":"23","author":"Williams","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"2026080313231930000_jiag251-B29","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41579-024-01023-3","article-title":"Antimicrobial treatment and resistance in sexually transmitted bacterial infections","volume":"22","author":"Jensen","year":"2024","journal-title":"Nat Rev Microbiol"},{"key":"2026080313231930000_jiag251-B30","doi-asserted-by":"crossref","first-page":"dlab091","DOI":"10.1093\/jacamr\/dlab091","article-title":"High prevalence of circulating dual-class resistant Mycoplasma genitalium in asymptomatic MSM in Tokyo, Japan","volume":"3","author":"Ando","year":"2021","journal-title":"JAC Antimicrob Resist"},{"key":"2026080313231930000_jiag251-B31","first-page":"1017","article-title":"Moxifloxacin and sitafloxacin treatment failure in Mycoplasma genitalium infection: association with parC mutation G248T (S83I) and concurrent gyrA mutations","volume":"221","author":"Murray","year":"2020","journal-title":"J Infect Dis"},{"key":"2026080313231930000_jiag251-B32","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1136\/bmjsrh-2019-200384","article-title":"High rates of treatment failure for Mycoplasma genitalium among men and women attending a sexual health clinic","volume":"46","author":"Ovens","year":"2020","journal-title":"BMJ Sex Reprod Health"},{"key":"2026080313231930000_jiag251-B33","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s11904-025-00768-7","article-title":"Mycoplasma genitalium\u2014where are we at?","volume":"22","author":"Bradshaw","year":"2025","journal-title":"Curr HIV\/AIDS Rep"},{"key":"2026080313231930000_jiag251-B34","doi-asserted-by":"crossref","first-page":"103198","DOI":"10.1016\/j.eclinm.2025.103198","article-title":"Beyond behavioural change: prioritising structural solutions to control bacterial sexually transmitted infections","volume":"83","author":"Ong","year":"2025","journal-title":"eClinicalMedicine"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiag251\/68248735\/jiag251.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/234\/1\/e151\/68248735\/jiag251.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/234\/1\/e151\/68248735\/jiag251.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T17:23:28Z","timestamp":1785777808000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/234\/1\/e151\/8672798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,5,8]]},"published-print":{"date-parts":[[2026,8,3]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiag251","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7,15]]},"published":{"date-parts":[[2026,5,8]]}}}